Rinvoq copay card plus#

RINVOQ may cause serious side effects, including: What is the most important information I should know about RINVOQ? It is not known if RINVOQ is safe and effective in children under 12 years of age with atopic dermatitis. RINVOQ is safe and effective in children 12 years of age and older weighing at least 88 pounds (40 kg) with atopic dermatitis.

Adults and children 12 years of age and older with moderate to severe eczema (atopic dermatitis) that did not respond to previous treatment and their eczema is not well controlled with other pills or injections, including biologic medicines, or the use of other pills or injections is not recommended.

It is not known if RINVOQ is safe and effective in children with juvenile idiopathic arthritis, psoriatic arthritis, ulcerative colitis, or ankylosing spondylitis.

Adults with active ankylosing spondylitis when 1 or more medicines called TNF blockers have been used, and did not work well or could not be tolerated.

Adults with moderate to severe ulcerative colitis when 1 or more medicines called TNF blockers have been used, and did not work well or could not be tolerated.

Adults with active psoriatic arthritis when 1 or more medicines called TNF blockers have been used, and did not work well or could not be tolerated.

Adults with moderate to severe rheumatoid arthritis when 1 or more medicines called tumor necrosis factor (TNF) blockers have been used, and did not work well or could not be tolerated.

RINVOQ is a prescription medicine used to treat:

To learn about AbbVie’s privacy practices and your privacy choices, visit Arava and Plaquenil are registered trademarks of their respective owners. This assistance offer is not health insurance. Patients who are members of insurance plans that claim to reduce or eliminate their patients' out of pocket co-pay, co-insurance, or deductible obligations for certain prescription drugs based upon the availability of, or patient's enrollment in, manufacturer sponsored co-pay assistance for such drugs (often termed 'maximizer' programs) will have an annual maximum program benefit of $6,000.00 per calendar year. Restrictions, including monthly maximums, may apply. Offer subject to change or discontinuance without notice. Patients may not seek reimbursement for value received from the RINVOQ Complete program from any third-party payers. Patients residing in or receiving treatment in certain states may not be eligible. If at any time a patient begins receiving prescription drug coverage under any such federal, state, or government-funded healthcare program, patient will no longer be able to use the RINVOQ Complete Savings Card and patient must call RINVOQ Complete at 1.800.2RINVOQ to stop participation. Co-pay assistance program is not available to patients receiving prescription reimbursement under any federal, state, or government-funded insurance programs (for example, Medicare, Medicare Advantage, Medigap, Medicaid, TRICARE, Department of Defense, or Veterans Affairs programs) or where prohibited by law or by the patient’s health insurance provider. Eligibility: Available to patients with commercial prescription insurance coverage for RINVOQ who meet eligibility criteria.

Rinvoq copay card plus#

This benefit covers RINVOQ™ (upadacitinib) alone or for RINVOQ plus one of the following medications: methotrexate, leflunomide (Arava ®), or hydroxychloroquine (Plaquenil ®).

RINVOQ Complete Savings Card Terms and Conditions If at any time a patient begins receiving prescription drug coverage under any such federal, state or government-funded healthcare program, patient will no longer be able to use the RINVOQ Complete Savings Card and patient must call RINVOQ Complete at 1.800.2RINVOQ (1.800.274.6867) to stop participation. Co‑pay assistance program is not available to patients receiving prescription reimbursement under any federal, state or government‑funded insurance programs (for example, Medicare, Medicare Advantage, Medigap, Medicaid, TRICARE, Department of Defense or Veteran’s Affairs programs) or where prohibited by law or by the patient’s health insurance provider. †Eligibility: Available to patients with commercial prescription insurance coverage for RINVOQ™ (upadacitinib) who meet eligibility criteria.